[Treatment of spontaneous metastatic lung cancer with interleukin-12 gene-modified dendritic cells vaccine].
OBJECTIVE
Although many works have been done in treatment of metastatic lung cancer, effective method is lacked. This study was designed to investigate the treatment of spontaneous metastatic lung cancer by interleukin-12 (IL-12) gene-modified dendritic cells (DC) vaccine.


METHODS
The spontaneous metastatic lung cancer model, prepared by injection of the 3LL Lewis lung cancer cells into the footpads of C57BL/6 mice, were treated by subcutaneous vaccination with tumor antigen peptide Mut1-pulsed, IL-12 gene-modified dendritic cells (DC-IL-12/Mut1) derived from the normal bone marrow. After treatment, the lung weight, the number of lung metastatic nodes, the survival time of the tumor-bearing mice were observed, and the NK and CTL activities were respectively determined.


RESULTS
Compared with mice treated with Mut1-pulsed, control LacZ gene modified DC and untreated DC, tumor-bearing mice treated with DC-IL-12/Mut1 had the lightest lung weights (P < 0.01), the least lung metastatic node numbers (P < 0.01), the longest survival time (P < 0.01), also with the induction of potent CTL activity (P < 0.01) and NK activity (P < 0.01).


CONCLUSIONS
Tumor antigen-pulsed, IL-12 gene-modified dendritic cells have significant therapeutic effects on the spontaneous metastatic lung cancer, the possible mechanism involved with induction of CTL activity and enhancement of NK activity.
Chen
Ji-quan
JQ
Department of Respiratory Medicine, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P. R. China. erinyin@81890.net
Xiu
Qing-yu
QY
Shen
Ce
C
Yan
Ze-min
ZM
D000818:Animals; D018827:Carcinoma, Lewis Lung / Q000473:pathology; D003713:Dendritic Cells / Q000276:immunology*; D004195:Disease Models, Animal; D007167:Immunotherapy; D018664:Interleukin-12 / Q000235:genetics / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000628:therapy*; D015996:Survival Rate; D014407:Tumor Cells, Cultured; D014612:Vaccines / Q000008:administration & dosage
D014612:Vaccines; D018664:Interleukin-12